Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The Indian drug producer Cipla is hoping to find a partner or buyer for its biosimilars business. Cipla’s strength is in small-molecule chemistry, not biologic drugs, a company executive tells C&EN. The biosimilars business operates a plant and R&D center in Goa on India’s west coast. Cipla has developed biosimilars of Genentech’s cancer drugs Avastin and Herceptin but has not launched them in regulated markets. The company’s decision comes a few weeks after Merck KGaA agreed to sell its biosimilars business to Fresenius.
This article has been sent to the following recipient: